Actively Recruiting
Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes
Led by University of California, San Diego · Updated on 2025-08-01
276
Participants Needed
2
Research Sites
53 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Although procedural abortion in the second trimester is extremely safe, hemorrhage is one of the leading causes of morbidity and mortality. Tranexamic acid (TXA) is used commonly in obstetrics to prevent or manage intrapartum or postpartum hemorrhage and has been associated with decreased mortality and decreased blood loss at the time of birth. Some guidelines are recommending the use of TXA for both the prevention and management of bleeding for abortion care. However, there are currently no published studies assessing the association between TXA and bleeding outcomes for abortion procedures. This study will involve a randomized, placebo-controlled trial of pregnant patients aged 18 and older desiring dilation and evacuation (D\&E) for abortion or fetal demise at 18-24 weeks gestation. The primary aim is to determine whether prophylactic TXA has an effect on the need for additional interventions to control bleeding at the time of D\&E. The secondary aim is to determine whether prophylactic TXA has an effect on the mean quantitative procedural blood loss.
CONDITIONS
Official Title
Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to understand and sign informed consent
- Speaks English or Spanish language,
- Requesting pregnancy termination or procedural management of fetal demise - Intrauterine pregnancy, 18 weeks 0 days and 24 weeks and 0 days gestation
You will not qualify if you...
- History of or current thromboembolic event (deep vein thrombosis, stroke, pulmonary embolism)
- History of coagulopathy
- Anticoagulant use in the preceding five days
- Severe renal impairment
- Chorioamnionitis or sepsis
- Suspected placenta accreta spectrum
- Prophylactic uterotonics other than oxytocin given (or planned to be given) at the start of the D&E
- Known allergic reaction or hypersensitivity to TXA
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
University of California San Diego
San Diego, California, United States, 92037
Actively Recruiting
2
Planned Parenthood of the Pacific Southwest
San Diego, California, United States, 92101
Actively Recruiting
Research Team
K
Karen Greiner, MD, MPH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here